<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00560651</url>
  </required_header>
  <id_info>
    <org_study_id>CCL</org_study_id>
    <nct_id>NCT00560651</nct_id>
  </id_info>
  <brief_title>German Corneal Cross Linking Register</brief_title>
  <official_title>German Corneal Cross Linking Register</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suphi Taneri</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Franziskus Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Corneal Cross Linking is new treatment modality for patients with keratoconus. A keratoconus
      is characterized by progressive bulging and thinning of the eye's cornea. Keratoconus is a
      potentially severely sight impairing condition that may necessitate corneal transplantation
      in the progressive state.

      Corneal Cross Linking is designed to

        -  increase the cornea's mechanical stability

        -  to stop progression of bulging and thinning of the cornea

        -  to prevent the need for corneal transplantation

      Corneal Cross Linking is performed by

        1. Applying Riboflavin (Vitamin B2) eye drops every 2 minutes for 30 minutes to the cornea

        2. Illuminating the cornea with UV-light

      This register of Corneal Cross Linking procedures performed in Germany serves to

        -  gather long-term results

        -  detect rare complications and side-effects

        -  evaluate the efficacy in a large number of patients
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Anticipated">November 2027</completion_date>
  <primary_completion_date type="Anticipated">November 2027</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Keratometry</measure>
    <time_frame>yearly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Slit-lamp biomicroscopical findings</measure>
    <time_frame>yearly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best corrected Visual Acuity</measure>
    <time_frame>Yearly</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">7500</enrollment>
  <condition>Keratoconus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Cross linked eyes</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CCL (Corneal Cross Linking)</intervention_name>
    <description>Apply Riboflavin 0.1% in Dextran 500 20% in NaCl solution Illuminate with UV-light of 365 nm wave-length and 3.0 mW/cm² intensity at 5 cm distance</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Collagen cross linking</other_name>
    <other_name>Corneal collagen cross linking</other_name>
    <other_name>CCL</other_name>
    <other_name>3C-L</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with Corneal Cross Linking in Germany
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with keratokonus and treated with corneal cross Linking in Germany

        Exclusion Criteria:

          -  Non-ectatic conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suphi Taneri, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Augenklinik am St. Franziskus Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Berthold Seitz, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Homburg, Saar, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philip Maier, MD</last_name>
    <role>Study Director</role>
    <affiliation>Univer. Freiburg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claus Cursiefen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Univer. Erlangen, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Reinhard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univers. Freiburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arnd Heiligenhaus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Augenklinik am St.Franzsikus Hospital, Münster</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Walter Sekundo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univers. Mainz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Theo Seiler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IROC, Zürich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Atilla Osvald, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univers Homurg, Saar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan M Vetter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univers. Mainz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suphi Taneri, MD</last_name>
    <phone>49-251-987-7890</phone>
    <email>taneri@refraktives-zentrum.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saskia Oehler</last_name>
    <phone>49-251-987-7890</phone>
    <email>oehler@refraktives-zentrum.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Saar</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Berthold Seitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Atilla Osvald, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augenklinik am St. Franziskus Hospital</name>
      <address>
        <city>Münster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Suphi Taneri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arnd Heiligenhaus, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.dog.org/dog-kornea</url>
    <description>German Ophthalmological Society, Cornea section</description>
  </link>
  <reference>
    <citation>Koller T, Seiler T. [Therapeutic cross-linking of the cornea using riboflavin/UVA]. Klin Monbl Augenheilkd. 2007 Sep;224(9):700-6. Review. German.</citation>
    <PMID>17846959</PMID>
  </reference>
  <reference>
    <citation>Spoerl E, Mrochen M, Sliney D, Trokel S, Seiler T. Safety of UVA-riboflavin cross-linking of the cornea. Cornea. 2007 May;26(4):385-9. Review.</citation>
    <PMID>17457183</PMID>
  </reference>
  <reference>
    <citation>Seiler T, Hafezi F. Corneal cross-linking-induced stromal demarcation line. Cornea. 2006 Oct;25(9):1057-9.</citation>
    <PMID>17133053</PMID>
  </reference>
  <reference>
    <citation>Wollensak G, Aurich H, Pham DT, Wirbelauer C. Hydration behavior of porcine cornea crosslinked with riboflavin and ultraviolet A. J Cataract Refract Surg. 2007 Mar;33(3):516-21.</citation>
    <PMID>17321404</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2007</study_first_submitted>
  <study_first_submitted_qc>November 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2007</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>St. Franziskus Hospital</investigator_affiliation>
    <investigator_full_name>Suphi Taneri</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>keratoconus</keyword>
  <keyword>cornea</keyword>
  <keyword>cross linking</keyword>
  <keyword>UV-light</keyword>
  <keyword>riboflavin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

